From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Directa Plus – patent grant, a step towards addressing a large global market?

By Steve Moore | Monday 29 March 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has been granted an EU-wide patent covering the use of its G+® graphene in golf ball applications”. It emphasises this “the first step towards addressing a very large global market” and the shares have responded currently 4% higher to 106p, a £65 million market capitalisation. Is this justified?…

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

GLEN

Still Good Value in Glencore?

Tuesday »

SOS

Sosandar – FY Results And An SOS

 

URU

URU – Stink Upon Stink

 

Gold

Turning gold digital?

Saturday »

OPTI

Optibiotix: where is the TR1?

Time left: 22:40:07